Receipt of prior radiotherapy or condition for any reason that would contribute radiation dose that would exceed tolerance of normal tissues, at the discretion of the treating physician
Patients must have dermatology exam obtained within  days prior to registration to obtain baseline measurement; exam to be performed by treating physician or designated dermatologist
No evidence of residual involved lymph node disease or metastatic disease at the time of registration based on clinician assessment of imaging; the treating physician will determine if incidental lesions on imaging require workup to exclude metastatic disease; if based on review of images, the treating physician determines the patient to be stage III, then the patient is eligible
Patients who, in the judgment of their treating physician, have available standard of care therapies will be excluded
Patient with any underlying medical condition that the treating physician considers might be aggravated by treatment or which is not controlled (e.g. elevated troponin or creatinine, uncontrolled diabetes)
Total bilirubin =< . x ULN; or =<  x ULN (if upon judgment of the treating physician, it is believed to be due to EMH related to MF)
Patients must have recovered from the effects of any prior chemotherapy, as determined by the treating physician and study team, based in part on organ function defined above
Metastatic disease sites must be treatable with SRS (at discretion of treating physician)
Any other factors, including psychiatric or social, that in the opinion of the treating physician makes the patient an inappropriate candidate for a study
Diagnosis of VTE <=  days prior to study enrollment for which potential benefits of anticoagulation therapy to prevent recurrence of VTE are felt by the treating physician to exceed the potential harms
Treating physician intends to put participant on anticoagulation therapy for at least three months.
Note: (supportive transfusions will be allowed during treatment as deemed necessary by the treating physician)
Male patients must use a form of barrier pregnancy prevention approved by the investigator / treating physician during the study and for at least one month after treatment discontinuation (site-specific criteria applying to Avera only)
Patients must be willing to use brief courses (at least  hours) of steroids as directed for potential inflammatory side effects of the therapy if recommended by their treating physician
Untreated symptomatic hydrocephalus determined by treating physician.
Active and uncontrolled disease/infection as judged by the treating physician
Abnormal electrocardiogram (EKG) (study physician discretion)
Active and uncontrolled disease/infection as judged by the treating physician
Patients with higher risk of bleeding (deemed by the treating physician) or on anticoagulation
Medically and surgically appropriate to undergo neoadjuvant chemotherapy with TCH-P Taxotere (docetaxel), carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) regimen followed by standard of care local therapy as determined by their treating physician
Patients must be considered transplant eligible by the treating physician at time of study entry.
Rapidly progressive relapse requiring urgent chemotherapy as determined by treating physician
Deemed eligible for additional partial resection by treating physician and determined to be safe to receive  months of neoadjuvant therapy before planned surgery
Male subjects must, as appropriate to age and the discretion of the study physician:
Uncontrolled clinically significant arrhythmia, myocardial ischemia or congestive heart failure within the past  weeks, that is considered by the treating physician as a contraindication for initiation of chemotherapy;  discussion with the principal investigator is encouraged if further clarification is required
Patients must have surgically resectable disease in the opinion of the treating physician. For patients with a primary OPSCC, patients must be eligible for TORS (transoral robotic surgery)
Appropriate for treatment with sunitinib in the opinion of the treating physician
Able to walk and jog on a treadmill, in the opinion of the treating physician
Active and uncontrolled disease/infection as judged by the treating physician
Untreated symptomatic hydrocephalus determined by treating physician
Any other issue which, in the opinion of the treating physician, would make the patient ineligible for the study
Any other issue which, in the opinion of the treating physician, would make the patient ineligible for the study
Patients with a history of major psychiatric illness must be judged (by the treating physician) able to fully understand the investigational nature of the study and the risks associated with the therapy
Patients with significant malabsorption as determined by the treating physician
Any other medical or surgical condition or disease that, in the judgment of the treating physician, renders subject ineligible for high dose interleukin- therapy
Post-operative complications including significant neurological decline or hemorrhage that causes a drop in Karnofsky performance status (KPS) to less than  or renders the patient not suitable for chemoradiation as determined by their treating physician
Pulmonary function test is required, within  months of start; the treating physician will assess suitability by usual clinical criteria used for IL- treatment generally consistent with the Proleukin prescribing information; there is no specific minimum result specified by the protocol
Ejection fraction (EF) <% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g., echocardiogram [ECHO], multi-gated acquisition scan [MUGA]). A historic measurement of EF no older than  months prior to first administration of study drug can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or of the treating physician or both.
Any psychiatric, social or compliance issues that, in the treating physician opinion, will interfere with completion of the transplant treatment and follow up
Patients who, in the estimation of the treating physician or primary investigator, have had a clinical deterioration of their ECOG performance within the month prior to enrollment
Patient with other co-morbidities that in the opinion of the treating physician would be a contra-indication to protocol participation (e.g. inflammatory bowel disease)
No active or co-existing malignancy with life expectancy less than  months, sources for the determination of clinical significance by the treating physician will be included in the subjects medical record
Active and uncontrolled disease/infection as judged by the treating physician, sources for the determination of clinical significance by the treating physician will be included in the subjects medical record
Patients who are not candidates for, or who cannot tolerate intensive chemotherapy or blinatumomab, sources for the determination of clinical significance by the treating physician will be included in the subjects medical record
History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician.
Uncontrolled disease/infection as judged by the treating physician
Psychiatric disorder which, per treating physician discretion, may preclude compliance
The risk of disease recurrence with a five () year time period, as estimated by the treating physician, must be greater than or equal thirty percent (%)
Patients with other diseases that in the opinion of the treating physician pose a higher risk for treatment with ibrutinib therapy including active human immunodeficiency virus (HIV) infection and bleeding disorders
Any patient with metastatic esophageal cancer that is deemed a candidate for brachytherapy for local control or treatment of dysphagia as determined by treating physician
Presence of a concurrent active, incurable malignancy that may alter the outcome of the treatment for esophageal cancer as determined by the treating physician
Patients with performance status of =<  ( only allowed if decline in status is deemed related to\r\nlymphoma and felt potentially reversible by the treating physician)
Willingness to provide newly obtained tumor tissue at baseline and on treatment unless contraindicated by medical risk in the opinion of the treating physician.
Recommendation to undergo concurrent CRT, as determined by the treating physician, with a curative goal
Neurological and functional examination within  hours prior to registration by the treating physician
Subject would not benefit from additional cytotoxic chemotherapy as determined by the treating physician
Individuals who would benefit from additional cytotoxic chemotherapy as determined by the treating physician
Patients must be willing and able (in the opinion of the treating physician) to undergo two research biopsies for the investigational component of this trial
Any other issue which, in the opinion of the treating physician, would make the patient ineligible for the study
No dexamethasone use (or any other corticosteroid use with the purpose of treating cerebral edema) starting  days prior to the treatment planning MRI; patients may be tapered to meet this criterion if deemed safe by the treating physician
Deemed by the treating physician to be unable to eat regular meals
Active and uncontrolled disease/infection as judged by the treating physician
Patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance to this protocol
Physician recruitment will consist of surveying the physicians involved in treating patients on this pilot study; physician participation will be voluntary; physicians will indicate their consent through completion of the survey; survey instructions will include information about the voluntary nature of participation, confidentiality of responses and the minimal risk related to involvement
Patient deemed eligible for rectal spacer (Space OAR) placement by treating physician
Patients may not have impending organ compromise from disease as assessed by their treating physician
Repeat radiation in fields previously radiated will be allowed at the discretion of the treating physician
History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician
Patients must be anticipated to complete  cycles of therapy in the opinion of the treating physician
Active and uncontrolled disease/infection as judged by the treating physician
Conditions leading to inadequate gastrointestinal tract absorption as determined by the treating physician and/or investigator
Any known contra-indication to chemoembolization according to the treating physician
Physician plans to remove the stent within the duration of study follow-up
Breasts technically unsatisfactory for radiation treatment upon the discretion of the treating physician.
Able to receive outpatient treatment and follow-up at the treating institution.
Direct bilirubin equal to or less than . x ULN; or equal to or less than  x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis related to MF)
Suitability for concurrent chemoradiation therapy per treating physician's assessment
Patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance to this protocol
Patient must otherwise be a candidate for ASCT as determined by the treating physician
Untreated symptomatic hydrocephalus determined by treating physician
Prophylactic use of lamivudine in patients that have antibody positive (+), but no active infection will be up to the treating physician
History of clinically significant (as determined by the treating physician) atrial arrhythmia;
Group A : Individuals >  years of age with previously untreated AML who are able and should receive up to  cycles of induction chemotherapy with + as determined by the treating physician
Patients with creatinine > . times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease
All subjects must have history of histologically confirmed malignancy; brain biopsy is not required unless diagnosis is judged to be in doubt by the treating physician
Weight loss >  percent within  months prior to starting treatment that is determined by the investigator or treating physician to be directly related to tumor and not directly related local esophageal symptoms (e.g. dysphagia, odynophagia)
Patient must require treatment for symptomatic B-CLL as defined by the by the IWCLL/Hallek, December  criterion or as determined clinically necessary by the treating physician
Tamoxifen, Arimidex or other hormonal therapy is allowed; it may begin any time relative to the radiation at the discretion of the treating physician
Patients with rapid decline in neurological function as documented on exam and/or as per clinical judgment of treating physician (Cohort D)
Must have had all standard approved and unapproved therapies as deemed appropriate by the treating physician.
Active bleeding diatheses which in the opinion of the treating physician poses a significantly increased operative risk.
Presence of a concurrent active, incurable malignancy that may alter the outcome of the treatment for disease under treatment as determined by the treating physician
Other inherited metabolic disorders\r\n* Any other inherited metabolic disorder for which alloHCT is indicated and for whom, in the opinion of the treating physician, the patients best treatment option is with a haploidentical donor following non-myeloablative conditioning
Disease course appropriate for therapy initiation approximately - weeks from enrollment per treating physician.
Subjects must have received at least one line of chemotherapy prior to receiving adoptive T cell therapy and should have exhausted standard of care systemic therapy options; the decision to implement the T cell therapy will be at the discretion of the treating physician; the timing and total exposure to chemotherapy will depend on the tumor type in question (more systemic options for breast cancer; fewer for gastric cancer, for example); due to the heterogeneity of tumors being treated in this protocol, the discretion of the treating physician in terms of timing of immunotherapy will be critical
Serious medical illness that in the judgment of the treating physician places the patient at high risk of operative mortality
Progression of disease on the most recent restaging scan or clinically significant disease at the time of evaluation justifying enrolment in a trial in the opinion of the treating physician
Patients comprehensive metabolic panel (CMP) must be done no more than  weeks prior to informed consent and the CMP levels must be within acceptable institutional limits or to the discretion of the treating physician, which may be the principal investigator of the study
Absence of clinically relevant liver or kidney failure as deemed by the treating physician
Patients must be candidates for PD-L antibody (Ab) as determined by the treating physician
Patients must be candidates for ipilimumab as determined by the treating physician
Patients must be neurologically asymptomatic, or very minimally symptomatic, as judged by the treating physicians
Any psychiatric, social or compliance issues that, in the treating physician's opinion, will interfere with completion of the transplant treatment and follow up
The following pre-study tests should be obtained within  days prior to registration in accordance with good medical practice; results of these tests do not determine eligibility and minor deviations are acceptable if they do not impact patient safety in the judgment of the treating physician:
Patients will be limited to:\r\n* >=  years of age, OR\r\n* With co-morbidities that preclude treatment with standard platinum-based chemotherapy, as determined by the treating physician, OR\r\n* Karnofsky performance scale (KPS) =< , OR\r\n* Creatinine clearance <  cc/min
Patients must have recovered from prior surgery based on treating physician's discretion
Male subjects, as appropriate to age and the discretion of the study physician:
Patients with severe hepatic sinusoidal obstruction syndrome who in the judgment of the treating physician are not expected to have normalized bilirubin by Day  after enrollment.
Physician report/letter
Not a candidate for chemotherapy as determined by the treating physician
Tumors with a lumen sufficient to allow the positioning of the rectal applicator (standard probe/scope) confirmed by the treating physician
Concurrent treatment with hormone replacement therapy is permitted at the discretion of the treating physician; patients who have been taking hormonal/hormone blocking agents for breast cancer or breast cancer prevention or other indication are eligible; use of anti-hormonal agents (tamoxifen, medroxyprogesterone, aromatase inhibitors) is permitted at the discretion of the treating physician; documentation of concurrent medications is required
Patient must be appropriate for reduced intensity regimen, according to the treating physician
Patients with an active, uncontrolled systemic infection are not eligible until deemed controlled by the treating physician
Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician
NOTE: Results of the bone marrow biopsy and aspirate as well as cytogenetics are mandatory to register subjects onto study, which are indispensable to determine International Prognostic Scoring System (IPSS) category needed for eligibility; please note that it is not necessary to wait for the week , week , or week bone marrow and cytogenetic results prior to starting the next cycle unless deemed necessary by the treating physician; one example of this exception can include if the subject shows signs of progression, such as increased peripheral blood blast percentage; at that juncture, the treating physician may prefer to await the results prior to starting a new cycle; if a cycle is started, and based on the bone marrow results it is felt by the treating physician that the subject should not continue on treatment, please be sure to note this information on the case report forms at end of treatment
Direct bilirubin ? . x ULN; or ? x ULN (if upon judgment of the treating physician, it is believed to be due to EMH related to MF);
Patients with disseminated disease to the spine are not eligible, and MRI of spine must be performed prior to enrollment if the treating physician suspects disseminated disease.
Previously treated with ruxolitinib (unless not a good candidate for ruxolitinib therapy in the judgment of treating physician)
Patients with significant malabsorption as determined by the treating physician
Good candidate for treatment per protocol in the judgement of the principle investigator (PI) and/or treating physician follow stimulation
Partial mastectomy so extensive that the cosmetic result is fair or poor prior to HG-PBI as determined by the treating physician
Uncontrolled undercurrent illness that in the opinion of the treating physician would contraindicate the use of the drug
Positive stool guaiac, excluding hemorrhoids or documented radiation-induced proctitis, if test is performed at the discretion of the treating physician (stool guaiac test is not required to screen for eligibility)
Active and uncontrolled disease/infection that in the opinion of the treating physician and principal investigator may affect the ability to participate in the trial or put the patient at unduly high risk
Currently enrolled in study - and benefiting from therapy as determined by treating physician
Non-CNS progression of disease as assessed by the investigator/treating physician, for which a change in systemic therapy is planned OR achievement of stable or responsive non-CNS disease for which a holiday from the current systemic therapy is planned, as assessed by the investigator/treating physician
Appropriate candidate for systemic immune-chemotherapy such as the standard rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (RCHOP)  cycles as determined by the treating physician
Total bilirubin =<  x IULN except when in the opinion of treating physician is due to direct involvement of leukemia (e.g. hepatic infiltration or biliary obstruction due to leukemia) or Gilberts disease
Patients on anticonvulsant therapy may continue these at the discretion of their treating physician; however, it is recommended that anticonvulsant levels be checked periodically as clinically indicated if possible
The patient is deemed by their treating physician to be at low risk of recurrence from previous malignancies.
Any condition that, in the opinion of the treating physician, would exclude the subject from receiving bevacizumab. Examples may include but are not limited to:
Willingness to undergo core biopsies at baseline and mid-cycle  unless contraindicated by medical risk in the opinion of the treating physician and discussed with the principal investigator
Patient has been compliant with therapy per treating physician
Prior radiation therapy that at the treating physician's discretion makes SABR unsafe
Had progressive disease while on crizotinib, as assessed by the investigator or treating physician.
History of clinically significant (as determined by the treating physician) atrial arrhythmia
Subjects with a significant history of malabsorption (e.g. celiac sprue, short bowel syndrome, or other, as determined by the treating physician) are excluded
Patients with other major medical or psychiatric illnesses which the treating physician feels could seriously compromise tolerance to this protocol
Recommendation to undergo concurrent chemoradiation, as determined by the treating physician
Have a plan by treating physician to receive FOLFOX or FOLFOX-Avastin standard therapy for colorectal cancer as a first-line chemotherapy treatment
No clinically significant infections as judged by the treating physician.
Active and uncontrolled disease (other than AML) or infection as judged by the treating physician
Patients must have surgically resectable disease, in the opinion of the treating physician
Active and uncontrolled disease/infection as judged by the treating physician
Significant co-morbidity that could affect the safety or evaluability of participants as assessed by the treating physician and or principal investigator
The patient has a medical or psychiatric condition that constitutes an unacceptable risk for participation in this trial, in the judgment of the treating physician
Treating physician must deem that SRS is appropriate treatment for the metastatic spinal lesion(s)
Psychiatric or medical conditions which, in the opinion of the treating physician, would not allow the patient to undergo the proposed treatments safely
Patients with a significant systemic illness that is not well-controlled in the opinion of the treating physician are not eligible
Tumor within the irradiated field is negatively impacting patients quality of life or threatening catastrophic complication if left untreated as determined by the treating physician
Active and uncontrolled disease/infection as judged by the treating physician
The patient's treating physician states that one of the lesions can be treated with SBRT
Stage IV disease, confirmed by biopsy or unequivocal radiographic evidence (note: staging scans are not required, but should be performed at treating physician discretion in accordance with standard guidelines)
Patients who, with their treating physician, choose to proceed with an allogeneic transplant at the time of remission will not be vaccinated and will come off study
Patient is judged to be mentally reliable to follow instructions and to keep appointments (Please note that mental reliability is not determined through any specific test rather it is ascertained by the treating physician through conversation at the time of consult)
Patients must have both a disease-specialist (rheumatologist/immunologist, or neurologist) physician and a bone marrow transplant physician evaluation at the treating center before a patient is considered eligible; both specialists must agree that the patient is a candidate for transplantation and patients with systemic lupus erythematosus (SLE) and multiple sclerosis (MS) must have failed standard therapies
Patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance to this protocol
Subject must be deemed a suitable candidate for regorafenib as per their treating physician.
Patients who are deemed eligible for transplant by their treating physician
VS surgery determined clinically necessary by the treating physician and scheduled within  weeks
No prior therapy for DLBCL, except =<  week of corticosteroids given on an emergent basis or as a temporizing measure (pre-phase where indicated by the treating physician)
Patient not eligible for (immediate) standard induction chemotherapy based on the opinion of the treating physician and the frailty score
A tumor lesion that can be safely biopsied as judged by the treating oncologist and physician performing the procedure and has not been radiated
Active and uncontrolled disease/infection as judged by the treating physician
Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment; similarly, any unstable medical condition that in the opinion of the treating physician or study investigators, would interfere with determination of the study objectives
Patient with any underlying medical condition that the treating physician considers might be aggravated by treatment or which is not controlled (e.g., elevated troponin or creatinine, uncontrolled diabetes)
Active serious infection that at the discretion of treating physician makes patient ineligible for chemotherapy
Participants With AML: treatment naive or relapsed for whom experimental therapy is appropriate (as assessed by their treating physician) For Part B:
Any co-morbid condition of sufficient severity to limit full compliance with the protocol per assessment by the individual treating physician
Patients whose treatment plans include continuing chemotherapy after ablation as per the treating physician
Previously received and are continuing to derive clinical benefit from iniparib, as monotherapy or in combination with chemotherapy, as determined by the treating physician.
Subjects with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise compliance with this protocol
Patients must have adequate hepatic, hematologic and renal functioning to be able to be administered anastrozole at the discretion of the treating physician
Patients with impaired decision making as determined by the treating physician
Have contraindications to functional testing or yoga participation according to the treating physician or the physician's designee
Physical or psychological contraindication to participation at the discretion of the treating physician
Patients identified by treating physician as being unsuitable for contact
CLINICIAN: Is the treating physician providing care to a patient enrolled to the study
Patients who have received radiation without adequate relief from metastatic bone pain as determined by the patient and treating physician
Significant intracranial pressure as per treating physician that may require surgical intervention.
Written physician approval
Subjects with an uncontrolled, active infection; subjects with viremia (cytomegalovirus or other) may be enrolled, provided they are on active therapy and at the discretion of the treating physician
RENAL CANCER: Metastatic disease, in the opinion of the treating provider
Treatment entails significant risk for symptomatic mucositis likely to require opioid analgesia, as per the discretion of treating physician/nurse practitioner (NP)
Permission from treating/study physician to participate in RT
Physically able to exercise and have physician consent from their treating physician to start a physical activity program
Approved to be contacted by the treating urologist
Patients who, in the opinion of the treating physician, have a medical condition, or currently take medications, which are felt to contraindicate safe or effective administration of the standard three drug anti-emetic regimen used in this study
Deemed disease free by the treating physician
Treating physician approval to participate in study
Deemed appropriate for treatment in the prone position by the treating physician
Patients who are taking medications (including minocycline) or have conditions that potentially preclude use of the study medication or intervention as determined by the treating physician
No prior renal disease that in the opinion of the attending physician would make the patient ineligible to receive the study drug
Patients continuously taking any minocycline within the last  days; patients who have conditions that potentially preclude use of minocycline as determined by the treating physician
Patients who are taking minocycline for other conditions, as determined by the treating physician
CLINICIAN: Is the treating physician providing care to a patient enrolled to the study
Minocycline trial only: patients who are taking medication or have conditions that potentially preclude use of minocycline, as determined by the treating physician
The patients current treatment plan must include an anti-emetic regimen with either ondansetron or granisetron on a scheduled basis; patients may also receive dexamethasone for antiemetic prophylaxis during the acute phase at the discretion of the treating physician; patients ?  years old may also receive aprepitant in conjunction with dexamethasone for antiemetic prophylaxis at the discretion of the treating physician
The opinion of the treating physician determines it is not medically safe to participate in the study
Patients will receive standard of care systemic treatment for underlying solid malignancy as deemed necessary by treating physician
Patients with any condition that precludes use of the study medication as determined by the treating physician
Patients getting radiation therapy are allowed at the discretion of the treating physician
Any psychiatric, social or compliance issues that, in the treating physician opinion, will interfere with completion of the transplant treatment and follow up
Significant medical or psychiatric problems which would make the subject a poor protocol candidate, in the opinion of the treating physician
Subjects must be accessible for treatment, adverse event tracking and follow-up as determined by the treating physician
Patient must NOT be in liver failure as judged by the patients physician
For cohort A, only patients with metastatic cancer to the brain for whom their treating physician has planned to give immunotherapy as monotherapy are eligible for this study; this can be in the setting of a clinical trial or not
For cohort B, only patients with GBM for whom their treating physician has planned to give immunotherapy are eligible for this study; this can be in the setting of a clinical trial or not
Patients with intracerebral hemorrhage deemed significant by treating physician are excluded
Patients are healthy enough to be deemed surgical candidates by the treating physician
Need to be treated with taxane containing chemotherapy as determined by their treating physician
Patients in liver failure as judged by the patients physician
Patients selected for Ra- dichloride therapy for treatment of bone metastasis by their treating physician
Good operative candidate as determined by the treating physician and multidisciplinary team
Must have an MRI scan ordered by a treating physician
For patients who do not have a tissue diagnosis:\r\n* Non-oncologic severe co-morbidities suggesting a life span of less than two years if not treated, as determined by the potential subjects treating physician\r\n* If severe co-morbidities are present, the treating physician should indicate that a life span of  years is expected if treatments are effective\r\n* This exclusion is to prevent loss of the needed  year CT follow-up to establish a benign diagnosis for lesions lacking tissue diagnosis if extremely fragile subjects are enrolled and then experience an untimely, unrelated death
Participants must be eligible for preoperative chemotherapy for IBC as determined by the treating physician
Does not speak English as a primary language (as determined by the principal investigator [P.I.] or treating physician after discussion with a potential subject and his/her family)
Subjects with known hepatic insufficiency or cirrhosis as determined by either a prior diagnosing physician or at review at initial consultation; these disease entities do not have formal associated lab values and are thus a clinical diagnosis by the prior aforementioned physician
Patients who are acutely ill who are deemed by their treating physician as not suitable candidates for this study
Subject who is deemed by the treating physician to have a contraindication to definitive treatment
Patients who, with their treating physician, choose to proceed with an allogeneic transplant at the time of remission will not be eligible for randomization
Subject will not proceed with transplantation as either a decision not to proceed with transplantation has been made either on the recommendation of the treating physician or by the patient or a suitable donor could not be identified.
Stereotactic radiation treatment of stage I disease or adjuvant chemotherapy is allowed at the discretion of treating physician for the participating subject
Medical co-morbidities making surgery unsafe, as determined by the primary treating physician
Medically able to undergo primary cytoreductive surgery, at least  days and up to  days after starting study drug, as determined by treating physician
Serious underlying medical (including acute decompensated congestive heart failure) or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment; similarly, any unstable medical condition that, in the opinion of the treating physician or study investigators, would interfere with the study objectives
Medically able to undergo primary cytoreductive surgery, at least  days and up to  days after starting study drug, as determined by treating physician
Have the approval of their treating physician to receive the  week ibuprofen/placebo regimen ( mg twice a day and doses  hours apart); (physician must sign eligibility checklist prior to registration)
Seeing a participating physician for less than a year and expecting to see this physician at least once in the following year